Articles tagged "Hepatocellular carcinoma"

2022 American Transplant Congress
Impact of MMaT Policy on Transplant for Hepatocellular Carcinoma at a Single Center
S. Kodali¹, D. W. Victor², J. Corkrean², A. Shetty², C. Mobley², M. Hobeika², R. McMillan², E. A. Graviss³, D. T. Nguyen³, R. McFadden⁴, V. Ankoma-Sey², C. Egwim⁵, J. Galati², A. Saharia², R. M. Ghobrial²
¹Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Sugarland, TX, ²Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, ³Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, ⁴Department of Medicine, Hepatology, Houston Methodist Hospital, Houston, TX, ⁵Houston Methodist Hospital, Houston, TX
*Purpose: Hepatocellular carcinoma (HCC) is the most common primary malignant hepatic tumor. Currently, liver transplantation may be the optimal treatment for HCC. Patient selection criteria…
2021 American Transplant Congress
Given the Potential Impact on Liver Transplant Selection, Revisiting the Current Standard of Diagnosis of Hepatocellular Carcinoma
K. Amarell, B. Fisher, B. Park, K. Ko, B. Kallakury
Department of Pathology & Laboratory Medicine, Georgetown University School of Medicine, Washington, DC
*Purpose: The current standard of diagnosis of hepatocellular carcinoma (HCC) relies on non-invasive radiographic methods, namely computerized tomography (CT) and/or magnetic resonance imaging (MRI). However,…
2021 American Transplant Congress
Effects of TIPS on Transplant Outcomes for HCC
C. L. Hanlon¹, D. Toy¹, Y. Liu¹, S. Zhou¹, K. Zhou², J. Kahn², L. Yuan²
¹Internal Medicine, University of Southern California, Los Angeles, CA, ²Internal Medicine - Department of Gastroenterology and Hepatology, University of Southern California, Los Angeles, CA
*Purpose: The purpose of this study is to examine effects of TIPS placement on response to locoregional therapy (LRT) and clinical outcomes after liver transplantation…
2021 American Transplant Congress
Immunotherapy of Dc-cik Cells in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation
S. Hsu, L. Jeng, H. Yang, A. Thorat
China Medical University Hospital, Taichung, Taiwan
*Purpose: Dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance in some…
2021 American Transplant Congress
Review of 10-Year Liver Explant Pathology Impact on Outcomes in a Single Center
Y. K. Kwon¹, L. Sher¹, S. Khemichian², J. Kahn², Y. Genyk¹
¹Hepatobiliary and Abdominal Transplant Surgery, University of Southern California, Los Angeles, CA, ²Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA
*Purpose: Explant pathology (EP) is an important prognostic factor after liver transplantation (LT) for hepatocellular carcinoma (HCC). The purpose of this study was to correlate…
2021 American Transplant Congress
Intrahepatic Spatial Location of HCC Recurrence Following Loco-regional Therapy for Solitary Tumors Predicts a Higher Oncologic Risk & Increased Recurrence Post-transplant
A. Mathur, E. Baughan, S. Haider, A. Griesemer, T. Kato, J. Emond
Columbia University, New York, NY
*Purpose: Loco-Regional therapy (LRT) for hepatocellular carcinoma (HCC) patients is an established bridge to Orthotopic Liver Transplantation (OLT). However, no large cohort data exist correlating…
2021 American Transplant Congress
Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era
K. Okumura, H. Sogawa, G. Veillette, D. John, T. Diflo, R. Bodin, D. C. Wolf, S. Nishida
Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY
*Purpose: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplantation(LT) in patients with hepatitis C virus (HCV). The aim of this study was…
2021 American Transplant Congress
The Role of Histone Acetylation/methylation Mediated Epigenetic Modifications in the Pathogenesis of Non-alcoholic Steatohepatitis-associated Liver Carcinogenesis
P. K. Rajan¹, U. Utibe-Abasi¹, J. D. Sanabria¹, M. Banerjee², G. Smith¹, M. S. Schade¹, J. Sanabria¹, K. Sodhi¹, S. Pierre², Z. Xie², J. I. Shapiro², J. Sanabria¹
¹Department of Surgery, Marshall University, Huntington, WV, ²Marshall Institute for Interdisciplinary Research (MIIR), Marshall University, Huntington, WV
*Purpose: Hepatocellular carcinoma (HCC) is one of the most aggressive human cancers and is characterized by an acquisition of multiple abnormal phenotypes driven by epigenetic…
2021 American Transplant Congress
Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything
G. T. Schnickel¹, J. Parekh¹, Y. Kono², J. Berumen¹, V. Ajmeera², K. Mekeel¹
¹Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California San Diego, San Diego, CA, ²Division of Gastroenterology, Department of Medicine, University of California San Diego, San Diego, CA
*Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…
2021 American Transplant Congress
Outcomes of Downstaging Hepatocellular Carcinoma (HCC) to within Milan Criteria Before Liver Transplantation (LT): A Multicenter Analysis of the “All-comers” Protocol
B. Natarajan¹, P. Tabrizian², M. Hoteit³, C. Frenette⁴, T. Ghaziani⁵, R. Dhanasekaran⁵, N. Parikh⁶, J. Guy⁷, A. Shui¹, S. Florman², F. Yao¹, N. Mehta¹
¹UCSF, SF, CA, ²Mt Sinai, NY, NY, ³U Penn, Philadelphia, PA, ⁴Scripps, La Jolla, CA, ⁵Stanford, Palo Alto, CA, ⁶U Michigan, Ann Arbor, MI, ⁷CPMC, SF, CA
*Purpose: Patients with HCC meeting UNOS-downstaging (DS) criteria (1 lesion 5.1-8 cm, 2-3 lesions at least one 3.1-5 cm and total tumor diameter (TTD) ≤8…